Table 2.

Crude and adjusted estimates for associations with rollout time

	Descriptive		Univariable			Multivariable
Characteristic	N = 229 a	Mean rollout time months (SD)	β	95% CI	p-value	β	95% CI	p-value
Submission sequence
Sequential	103.0 (45.0%)	27.7 (14.5)	–	—		–	—
Parallel	126.0 (55.0%)	13.7 (4.7)	−14.0	−17.0, −11.0	<0.001	−14.0	−17.0, −12.0	<0.001
Country
Australia	95.0 (41.5%)	16.6 (11.2)	–	—		–	—
Canada	134.0 (58.5%)	22.4 (12.7)	5.8	2.6, 9.0	<0.001	6.0	3.4, 8.7	<0.001
Therapeutic area
Non-oncology	117.0 (51.1%)	21.3 (14.2)	–	—		–	—
Oncology	112.0 (48.9%)	18.6 (10.1)	−2.6	−5.9, 0.6	0.11	−1.9	−4.6, 0.8	0.2
Expedited review
Non-expedited	180.0 (78.6%)	20.5 (12.5)	–	—		–	—
Expedited	49.0 (21.4%)	18.1 (12.4)	−2.4	−6.3, 1.6	0.2	−5.5	−8.7, −2.2	<0.001
Conditional review
Conditional	34.0 (14.8%)	16.4 (5.8)	–	—		–	—
Non-conditional	195.0 (85.2%)	20.6 (13.2)	4.2	−0.4, 8.7	0.070	5.7	1.8, 9.7	0.005
Top R&D spenders
Top	101.0 (44.1%)	18.5 (10.7)	–	—		–	—
Non-top	128.0 (55.9%)	21.1 (13.6)	2.6	−0.7, 5.8	0.12	0.6	−2.2, 3.3	0.7
Year HTA recommendation
2019	41.0 (17.9%)	18.4 (12.0)	–	—		–	—
2020	35.0 (15.3%)	21.7 (17.7)	3.3	−2.4, 9.0	0.3	1.8	−2.6, 6.2	0.4
2021	48.0 (21.0%)	19.4 (10.9)	1.0	−4.2, 6.3	0.7	−1.4	−5.5, 2.7	0.5
2022	65.0 (28.4%)	19.9 (11.9)	1.5	−3.5, 6.4	0.6	0.8	−3.0, 4.7	0.7
2023	40.0 (17.5%)	20.9 (10.2)	2.5	−3.0, 8.0	0.4	−0.6	−4.8, 3.7	0.8

Note: The “Multivariable” column shows mutually adjusted estimates adjusting for submission strategy, country, therapeutic area, expedited review, conditional review, top R&D spender, and year of HTA recommendation. The “Univariable” column shows unadjusted estimates. Significant p values are highlighted in bold.

^an (%).

CI, Confidence interval.